Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS

Jan Philipp Radtke1,2✉, Francesco Giganti3,4✉, Manuel Wiesenfarth5, Armando Stabile4,6,7,8, Jose Marenco6, Clement Orczyk4,6, Veeru Kasivisvanathan4,6, Joanne Nyaboe Nyarangi-Dix1, Viktoria Schütz1, Svenja Dieffenbacher1,2, Magdalena Görtz1, Albrecht Stenzinger9, Wilfried Roth9,10, Alex Freeman11, Shonit Punwani3,12, David Bonekamp2, Heinz-Peter Schlemmer2, Markus Hohenfellner1, Mark Emberton4,6, Caroline M. Moore4,6

1 Department of Urology, University Hospital Heidelberg, Heidelberg, Germany, 2 Department of Radiology, German Cancer Research Center, Heidelberg, Germany, 3 Department of Radiology, University College London Hospital NHS Foundation Trust, London, United Kingdom, 4 Division of Surgery & Interventional Science, University College London, London, United Kingdom, 5 Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany, 6 Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 7 Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy, 8 Vita-Salute San Raffaele University, Milan, Italy, 9 Institute of Pathology, University of Heidelberg, Heidelberg Germany, 10 Institute of Pathology, University Medicine Mainz, Mainz, Germany, 11 Department of Pathology, University College London Hospital, London, United Kingdom, 12 Centre for Medical Imaging, University College London Hospitals NHS Foundation Trust, University College London, London, United Kingdom

✉ These authors contributed equally to this work.
‡ These authors are first authors on this work.
✉ j.radtke@dkfz-heidelberg.de

Abstract

Background
Risk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy-naïve men.

Material and methods
The original RM was based on data of 670 biopsy-naïve men from Heidelberg University Hospital who underwent mpMRI with PI-RADS scoring prior to MRI/TRUS-fusion biopsy 2012–2015. Validity was tested by a consecutive cohort of biopsy-naïve men from Heidelberg (n = 160) and externally by a cohort of 133 men from University College London Hospital (UCLH). Assessment of validity was performed at fusion-biopsy by calibration plots, receiver operating characteristics curve and decision curve analyses. The RM's
The decision-making process of prostate cancer (PC) diagnosis is still controversial. The traditional approach we have taken in diagnosing PC, with raised prostate specific antigen and transrectal prostate ultrasound-guided (TRUS)-biopsy, do not appear to result in overall mortality benefit yet do lead to overdiagnosis and overtreatment of indolent disease [1]. The introduction of multiparametric magnetic resonance imaging (mpMRI) of the prostate has significantly improved the diagnostic accuracy of radiology in PC [2–7]. This has led to a higher detection rate of clinically significant PC (sPC) by means of targeted biopsies [7–9]. In addition, approaches using upfront MRI and targeted biopsies help to reduce the diagnosis of clinically indolent disease [7–9].

The implementation of clinical data with mpMRI findings has become of significant importance for urologists in order to better stratify those men who may deserve (or not) a prostate biopsy [10,11]. At this regard, there has been a considerable interest in developing new clinical tools and multivariable risk calculators (RC) and models (RM) able to predict the probability of a patient to harbour sPC, including data from mpMRI [10–15]. There is evidence suggesting that the addition of mpMRI findings to clinical information could increase the accuracy of diagnosis, but only few of these models have been either internally or externally validated [10,11,15]. Therefore, there is a need of further robust studies to develop more accurate RMs [16].

The purpose of this study was to validate a previously published RM predicting the probability of harbouring clinical sPC based on clinical parameters and mpMRI features focusing on cohorts of biopsy-naïve men undergoing mpMRI and subsequent prostate biopsy [10].
Material and methods

Study population

The study population comprised 160 consecutive biopsy-naïve patients from University Hospital Heidelberg and 139 men from University College London Hospital (UCLH). At Heidelberg, patients were enrolled and registered into a prospective database assessing MRI-targeted/TRUS-fusion biopsy between 2012 and 2017. Institutional review board approval was obtained (S011/2011) and all subjects provided written informed consent. Subgroups were previously reported [10,17]. The original RM-development contained data of patients undergoing MRI and fusion-biopsy between 2012–2015 [10]. Data of the 160 consecutive subjects in the present study, who underwent MRI and fusion-biopsy from 2016–2017, were not used in original RM-development. At UCLH, institutional review board exemption was granted from the local joint research office. The subgroup from UCLH consisted of 139 consecutive men undergoing transperineal prostate biopsy agreed to be sampled with additional targeted biopsy directed to suspicious lesions on prostate mpMRI from 2010–2012.

Data were retrospectively analysed. Inclusion criteria were suspicion of PC based on prostate specific antigen (PSA) or digital rectal examination (DRE), mpMRI with Prostate Imaging Reporting and Data System (PI-RADS) version 1.0 scoring according to the European Society of Urogenital Radiology guidelines and fusion-biopsy [18]. Men under active surveillance and men who had missing data were excluded (S1 Fig). Of all 299 biopsy-naïve men, full data on PI-RADSv1.0, biopsy-outcome, PSA, age, DRE, prostate volume (PV), PSA-density, lesions on TRUS and the European Randomised Study of Screening for Prostate Cancer Risk calculator (ERSPC-RC3) were available for 293 men (160 from Heidelberg and 133 from UCLH). Those samples served for validation and for comparisons to ERPSC-RC3, PI-RADSv1.0 and combined ERSPC-RC3 and PI-RADSv1.0.

Imaging

All mpMRI examinations were performed using a 3-Tesla-system (Magnetom, Siemens, Erlangen, Germany) using a multichannel-body-surface coil at Heidelberg and two scanners (one 1.5 Tesla- and one 3-Tesla-scanner (Avanto and Verio, Siemens, Erlangen, Germany) at UCLH, as previously reported [10,19]. In Heidelberg, all image analyses were prospectively performed according to PI-RADSv1.0 by or under supervision of expert uroradiologists (HPS, DB, MCR, 7–18 years of experience in prostate-MRI). In this scoring system every parameter T2WI, DWI and DCE is scored on a five-point scale separately. Additionally, each lesion is given an overall score, to predict its chance of being a clinically sPC. According to the PI-RADS guidelines for Version 1, no dominant sequence for different zones in which the lesion occur, as e.g. DWI for peripheral zone in Version 2, were applied.

For the UCLH cohort, each scan was retrospectively reported by a radiologist highly-experienced in prostate-MRI according to PI-RADSv1.0 (FG, 5 years of experience) [18]. This was done to make results from the two subgroups comparable, as the original prospective MR reading at UCLH was performed according to a 5-point Likert scale, but not PI-RADSv1.0. To detect potential differences or drawbacks of the RM using PI-RADSv1.0, all scans were retrospectively reported using PI-RADSv2.0.

Biopsy protocol

Transperineal grid-directed biopsy performed under general anaesthesia is the standard technique at both sites, whose sPC-detection accuracy has been validated [17,19]. At Heidelberg, all men underwent transperineal fusion-targeted biopsy (FTB) with rigid (BiopSee, MedCom,
Darmstadt, Germany) or elastic (Uronav, Invivo, Gainesville, USA) software-registration of MRI-suspicious lesions first (2–5 cores, median 2 per lesion) and then standard biopsy (SB) adjusted to PV (median 24 cores, according to the Ginsburg scheme) [17]. At UCLH, transperineal cognitive targeted biopsies were performed using the Hitachi Preirus (Hitachi Aloka Medical, Wallingford, USA) first, followed by SB using the Barzell 20-sector scheme [20]. Thus, both SB techniques were performed transperineally with an extended number of cores.

**Histopathology**

Histopathological analyses were performed by or under supervision of uropathologists specialized in prostate assessment according to International Society of Urological Pathology standards. sPC was defined as Gleason score (GS) \( \geq 3+4 \) (WR, AS, AF).

**Assessment of the ERSPC-RC3**

The ERSPC-RCs ([www.prostatecancer-riskcalculator.com](http://www.prostatecancer-riskcalculator.com)) are prediction models based on data of men in the ERSPC Rotterdam [21]. ERSPC-RC3 uses TRUS lesions, DRE, TRUS-measured PV and PSA. RC3 calculates the risk of finding any higher-grade (GS \( \geq 3+4 \)) and/or locally advanced (T-stage \( \geq T2c \)) PC in a conventional random-biopsy for men who have never been screened [21]. We retrospectively analysed ERSPC-RC3 on both subcohorts. ERSPC-RC3 were calculated manually per single patient using the original online RCs. These ERSPC-RCs were also used to combine ERSPC and PI-RADSv1.0 (ERSPC-R3+PI-RADSv1.0).

**Statistical analysis**

Patient demographics, MRI and biopsy results were analysed descriptively, according to START recommendations (Table 1) [22]. Differences of the subcohorts of both sites were detailed (Table 2). For further information on how the RM was derived, see the original manuscript [10]. The regression equations were as follows:

\[
\log \left( \frac{\pi_i}{1 - \pi_i} \right) = -2.206 + 1.056 \log(PSA_i) - 0.021 \text{volume}_i + 0.018 \text{age}_i \\
+ 1.407 I(DRE \geq cT2) - 0.156 I(PIRADS_i = 2) + 0.627 I(PIRADS_i = 3) \\
+ 1.533 I(PIRADS_i = 4) + 2.081 I(PIRADS_i = 5)
\]

**Discrimination**

Discrimination of ERSPC-RC3, PI-RADSv1.0, ERSPC-RC3+PI-RADSv1.0 and the RM were compared using Area-under-the-curve (AUC) of receiver-operating-characteristic (ROC) curve analysis (Fig 1). Statistical differences between predictive models were analysed using DeLong’s test and Holm adjustment for multiple testing (Table 3).

**Calibration of the RM**

The extent of over- or underestimation of predicted probabilities relative to observed probabilities of sPC was explored graphically using calibration plots for both subcohorts. The calibration plot demonstrated that the RM overestimates event probabilities at UCLH (Fig 2). This seems to be mainly due to major differences between the prevalences of sPC in the Heidelberg training cohort and the UCLH validation cohort (46% and 29%, respectively). It is well known that one has to be cautious about extrapolating risk models built on populations very different from the population of interest [23]. Although the prevalence in the general population is comparable in Germany and the United Kingdom, the prevalence in academic centers might be...
### Table 1. Study population and results according to START criteria.

Patients’ demographics including baseline clinical parameters, MRI and MRI/TRUS-fusion biopsy results according to START criteria.

|                                      | Men included in analysis, n | Median Age, years (IQR) | Median prebiopsy PSA-Level (IQR), ng/ml | Suspicious DRE findings (≥T2), n (%) | Median prostate volume (IQR), ml | Median PSA density (IQR) | Men with PI-RADS≥3 lesions on mpMRI, n (%) | Number of lesions PI-RADS≥3 | Patients with one PI-RADS≥3 lesion | Patients with > 1 PI-RADS≥3 lesions | Overall PI-RADS score 3 lesions, n (% of PI-RADS≥3) | Overall PI-RADS score 4 lesions, n (% of PI-RADS≥3) | Overall PI-RADS score 5 lesions, n (% of PI-RADS≥3) | Biopsies per patient, median (IQR) | Systematic biopsies per patient, median (IQR) | FTB per patient and per lesion, median (IQR) | Overall detection rate of prostate cancer, n (%) | Men with significant prostate cancer, n (% of all men) |
|-------------------------------------|-----------------------------|-------------------------|----------------------------------------|--------------------------------------|-------------------------------|------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| **Men included in analysis, n**     | 293                        |                         |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Median Age, years (IQR)**         |                            | 65 (58–70)              |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Median prebiopsy PSA-Level (IQR), ng/ml** |                  | 7.2 (5.0–11.5)          |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Suspicious DRE findings (≥T2), n (%)** |                  | 104 (35)                |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Median prostate volume (IQR), ml** |                            | 42 (30–60)              |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Median PSA density (IQR)**        |                            | 0.16 (0.11–0.299)       |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Men with PI-RADS≥3 lesions on mpMRI, n (%)** |                  | 259 (88)                |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Number of lesions PI-RADS≥3**     |                            | 319                     |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Patients with one PI-RADS≥3 lesion** |                        | 199                     |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Patients with > 1 PI-RADS≥3 lesions** |                        | 60                      |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Overall PI-RADS score 3 lesions, n (% of PI-RADS≥3)** |          | 127 (40)                |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Overall PI-RADS score 4 lesions, n (% of PI-RADS≥3)** |          | 102 (32)                |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Overall PI-RADS score 5 lesions, n (% of PI-RADS≥3)** |          | 90 (28)                 |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Biopsies per patient, median (IQR)** |                        | 27 (24–30)              |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Systematic biopsies per patient, median (IQR)** |          | 23 (19–26)              |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **FTB per patient and per lesion, median (IQR)** |          | 4 (2–6), 2 (1–3)        |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Overall detection rate of prostate cancer, n (%)** |          | 176 (60)                |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |
| **Men with significant prostate cancer, n (% of all men)** |          | 114 (39)                |                                        |                                      |                               |                        |                                      |                                  |                                  |                                  |                                         |                                           |                                           |                                          |                                  |                                   |                                  |                                          |                              |

n: Number, IQR- Interquartile range, PSA- Prostate specific antigen, ng- nanogram, ml- milliliter, DRE- Digital rectal examination, TRUS- transrectal ultrasound, mpMRI- multiparametric Magnetic Resonance Imaging, PI-RADS- Prostate Imaging Reporting and Data System, FTB- Fusion targeted biopsy

https://doi.org/10.1371/journal.pone.0221350.t001

### Table 2. Study population and results according to START criteria dichotomized into different cohorts.

Differences in subgroups of UCLH and Heidelberg University Hospital for patient demographics, mpMRI PI-RADS scoring and biopsy results.

| No. of patients | Heidelberg cohort | UCLH cohort | p-value |
|-----------------|-------------------|-------------|---------|
| Patient demographics |
| Median PSA level in ng/ml (IQR) | 6.5 (4.9–11.0) | 7.6 (5.3–13.0) | **0.042** |
| Median age (IQR) | 65 (59–70) | 64 (58–69) | 0.391 |
| Median prostate volume, ml (IQR) | 40 (29–58) | 45 (33–52) | **0.018** |
| Digital rectal examination (DRE), ≥CT2, n (% of all patients) | 58 (36) | 46 (35) | 0.713 |
| PSA-density (IQR) | 0.18 (0.12–0.28) | 0.18 (0.16–0.21) | 0.947 |

| mpMRI PI-RADS score distribution (highest PI-RADS score per patient) |
|---------------------------------------------------------------------|
| No lesion/PI-RADS 1 (%) | 13 (7) | 1 (1) | 0.154 |
| PI-RADS 2 (%) | 9 (6) | 11 (8) |        |
| PI-RADS 3 (%) | 50 (31) | 41 (31) |        |
| PI-RADS 4 (%) | 44 (28) | 38 (29) |        |
| PI-RADS 5 (%) | 44 (28) | 42 (32) |        |

| Biopsy results |
|-----------------|---------|
| Median No. of cores (IQR) | 28 (26–32) | 26 (24–28) | 0.995 |
| Median No. of systematic cores (IQR) | 24 (23–24) | 24 (24–24) | 0.889 |
| Median No. of targeted cores (IQR) | 4 (3–6) | 2 (1–4) | 0.614 |
| No. of any prostate cancers (% of all men) | 110 (60) | 58 (44) | 0.061 |
| No. of significant prostate cancers (% of all men) | 76 (48) | 38 (29) | **0.019** |

UCLH- University College London Hospital, IQR- Interquartile range; mpMRI- multiparametric Magnetic resonance imaging, SB- systematic biopsies, TB- targeted biopsies, PI-RADS- Prostate imaging reporting and data system, PC- prostate cancer, TRUS- transrectal ultrasound, PSA- prostate specific antigen

https://doi.org/10.1371/journal.pone.0221350.t002
variable. Therefore we thought to update our RM in terms of prevalence-adjustment and give both, the original and the adjusted risk model.

Adjustment procedure for different prevalences

A modification of the nomogram to the present situation is to use the prior correction strategy described e.g. in Prentice and Pyke [24] and Janssen et al. [25].

Thereby, we correct the intercept of the RM by subtracting the log odds of the prevalence in the development cohort (0.456) and adding the log odds of the prevalence in the ERSPC-RC3 cohort (0.245) to provide equal calibration-in-the-large of the two prediction models:

\[
\text{logit}(\pi_i) = -3.623 - \text{logit}(0.456) + \text{logit}(0.245) + 0.550 \log(\text{PSA}_i) - 0.020 \text{volume}_i + 0.034 \text{age}_i + 0.712 \text{I}(\text{DRE}_i \geq \text{cT2}) + 0.299 \text{I}(\text{PI-RADS}_i = 2) + 1.198 \text{I}(\text{PI-RADS}_i = 3) + 1.841 \text{I}(\text{PI-RADS}_i = 4) + 3.094 \text{I}(\text{PI-RADS}_i = 5)
\]

with predictors PSA, prostate volume (in ml), DRE results, age (in years) and PI-RADSv1.0 [10].

However, note that this requires assumptions about the distribution of the population characteristics that might be critical. The resulting RM shifts the probabilities of sPC while keeping the scale fixed (the odds ratios of the predictors remain the same), thus only the last line of the nomogram is changed. This implies that discrimination performance is not affected.

Decision curve analyses

Last, we assessed the clinical usefulness of the original and the prevalence-adjusted RM by using decision curve analysis (DCA) [26]. We compared the RM and ERSPC regarding its clinical usefulness on DCA, performing a recalibration with respect to the ERSPC prevalence (24.5%), as mentioned before (Fig 3C and 3D).
Statistical analyses were performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), packages ModelGood, DCA and rms [26]. Reporting followed Standards of Reporting of Diagnostic Accuracy (STARD) guidelines (S1 Table)[27].

Results

In total 293 men underwent mpMRI and subsequent fusion-biopsy. Of them, 160 underwent procedures in Heidelberg und 133 men at UCLH. Patient demographics, MRI and biopsy data are given in Table 1. sPC was detected in total 114 patients (39%). Stratification into centers revealed sPC in 76 men (48%) in the Heidelberg and 38 (29%) men in the UCLH cohort.

Differences on patients’ demographics, mpMRI and biopsy outcomes between the both subcohorts are given in Table 2.

The discrimination of the RM was compared to ERSPC-RC3, PI-RADSv1.0 and ERSPC-RC3+PI-RADSv1.0 using ROC curve analyses (Fig 1, Table 3). In the Heidelberg validation cohort, the RM reached a higher AUC (0.86), compared to ERSPC-RC3 (0.77), and PI-RADSv1.0 (0.79; section a of Fig 1, section a of Table 3). The RMs AUC was comparable to ERSPC-RC3+PI-RADSv1.0 (0.84). At UCLH, the discrimination of the RM (0.86) was superior to ERSPC-RC3 (0.77) and comparable to PI-RADSv1.0 (0.82) and ERSPC-RC3+PI-RADSv1.0 (0.82)(Table 3).
Calibration plots of the RM (Fig 2A and 2B) demonstrate that there are no untoward deviations of predicted from observed risk of sPC over the entire range in the Heidelberg subgroup. At UCLH, the calibration plot demonstrated systematic overestimation of the sPC probability for both, the RM as well as ERSPC-RC3 (Fig 2B), but for ERSPC-RC3 to a much smaller extend.

Fig 2. Calibration plots for the risk model and ERSPC-RC3 to predict sPC. a) Calibration plots for the Heidelberg validation cohort, b) Calibration plots for the UCLH validation cohort.

https://doi.org/10.1371/journal.pone.0221350.g002
In adjusted (with respect to the original ERSPC prevalence of 24.5% of sPC) DCA the RM had a higher net benefit in terms of accurately detecting patients with sPC compared to mpMRI and the ERSPC-RC (Fig 3C and 3D) [21]. The RM showed a benefit for sPC threshold probabilities above 10% at both centres (Fig 3C and 3D).

Discussion

The results of our study showed that the novel RM, combining clinical and MRI parameters discriminates well in both, a consecutive validation cohort of the same institution on whose patients the RM was developed, and an external cohort. The discrimination performance of the RM was similar in both cohorts and significantly better than the performance of ERSPC-RC3. This is in line with recent results demonstrating added benefit of MRI in combination with clinical parameters [11,15].
Second, this study shows that the present RM performs well in two different cohorts using different MRI scanners and radiologists with different experience in prostate-MRI. Our results furtherly support that standardized mpMRI reading is reliable not only within a nomogram combining MRI and clinical parameters, but also as a standalone screening test. The discrimination performance of expert MRI reading was comparable, with an AUC of 0.82 at UCLH and 0.79 in Heidelberg. However, DeLong's test demonstrated that adding clinical parameters within the RM significantly enhances the accuracy of MRI alone to predict sPC in Heidelberg, but not at UCLH.

A third point is the comparison to the clinical ERSPC-RC. Additional benefit of adding MRI to ERSPC-RC3 has recently been shown in a multicentric study, with comparable results [15]. Even if the novel RM outperforms the ERSPC-RC alone, our study could demonstrate that the ERSPC-RC3 alone has a good discrimination performance. Considering that Poyet et al. recently demonstrated that the performance of a nomogram depends on the number of biopsy cores and decreases with the increase of the cores taken, we could support the generalizability of the ERSPC-RC3, which was externally validated with an accurate AUC of 0.77 in both cohorts using extended biopsy protocols [21,28].

Additionally, in the light of the results of Poyet et al., who could demonstrate that an increased number of cores taken (12 core compared to 6–8 core) negatively influenced the performance of a validated risk model, the use of a robust reference test, combining extended SB and FTB with a median cores of 27, as in the present study, emphasizes the discrimination performance of the novel RM in the ROC curve analyses [28]. However, regarding the clinical applicability of the RM, we have to acknowledge that the RM systematically overestimated the sPC probability in a subgroup with lower prevalence (UCLH subgroup) than in the cohort on which the RM was developed (Heidelberg subgroup). Thus, the clinical applicability of the RM in the external validation needs to be discussed. In particular, this study emphasizes the prevalence-dependence of risk models.

To analyse the real net benefit of a novel RM, it has to be adjusted according to the actual prevalence of the considered population. This is critical, because one has to assume the prevalence of the cohort, as the prevalence is unknown in most cases. This is important, if one wants to extrapolate the RM and consecutively to introduce it in common clinical practice.

However, this is a general problem in any risk model. We acknowledge that any risk model is only applicable on comparable populations and extrapolation to populations with different characteristics is problematic. Alternatively, when different prevalences occur, the intercept has to be adjusted for correct risk assessment. However, we emphasized that this does not affect discrimination performance in external validation. Moreover this is a reflection to a general problem of risk modeling.

Furthermore, in clinical practice, both physicians and different patients have different trade-offs of individuals’ sPC risk. Therefore there are no single risk thresholds and DCA is the most informative tool to weigh the relative harm of potentially unnecessary biopsy and the benefit of diagnosing sPC.

In our study, the discrimination performance of the original RM, analyzed by ROC curve analyses (Fig 1, Table 3) was good in both, a cohort that is comparable in terms of prevalence to the cohort in which the model has been derived (Heidelberg), and also in a cohort, in which the prevalence is different (UCLH). It is well known that ROC curve analyses are not affected by prevalences. However, individuals' predicted probabilities of sPC are trivially affected by the prevalences. The predicted and the empirical sPC probability was visualized in calibration curves, demonstrating that the original model overestimated the probabilities due to prevalence differences (Fig 2B). In decision curve analyses the net benefit of the original model was therefore limited in the cohort in which the prevalence is smaller, because the patients’ individual
probability is overestimated (Fig 3B). After adjustment of the RM such that prevalences underlying the RM and ERSPC-RC are equivalent has been performed, as in the Material and methods section, the overestimation is extenuated (compare Fig 2B, in which the upper curve gives the calibration of the original model as compared to the adjusted one in the lower curve). This also affects the decision curve analysis, demonstrating improved benefit of the adjusted RM over a threshold probability from 0.10 to approximately 0.50 (Fig 3D).

Our study has limitations. First, as mentioned before, prevalence-dependence of the RM limits its generalizability. In order to correctly determine the individual's risk of harbouring sPC, it is mandatory to be aware of the sPC prevalence in the current population or to assume this to adjust the RM's intercept.

Both cohorts used a similar biopsy approach including MRI/TRUS-fusion and template SB with an extended number of biopsy cores. Therefore, we cannot clearly state how the RM performs on cohorts using different biopsy strategies (e.g. using widespread standard 12-core TRUS-biopsy). However, the application of a robust reference test is a strength of the study, and the relative poor performance of the 12-core TRUS-biopsy has been recently confirmed [3,4]. One might assume that differences occur due to different fusion-biopsy techniques. With regards to the biopsy approach the available data in the literature is rather scarce. The latest review and clinical trials were not able to show significant differences between cognitive and software-assisted biopsy for MRI-targeted cores, but one of the limitations given were limited amounts of studies or patients, respectively [29–32]. Additionally, Wysock et al. compared MRI/TRUS-fusion-guided biopsies versus visual estimated targeting in a prospective study including 125 men with suspicious lesions [33]. They found that MRI/TRUS-fusion-guided biopsies had a slightly improved cancer detection rate compared to visual estimation for GS ≥3+4 (20% versus 15%, p = 0.05). Puech et al. observed no difference in the cancer detection rate of PC for rigid software co-registration using software-guided compared to cognitive TB (53% versus 47%) [34]. However, Delongchamps et al. reported that cognitive fusion-biopsy was not significantly better than systematic biopsies, while both software co-registration devices tested (Esaote/MyLabTMTwice and Koelis/Urostation) significantly increased the cancer detection rate compared to systematic biopsies using logistic regression analysis in a cohort of 391 patients. In our study, the additional systematic biopsy part of the biopsy procedure was comparable in both centers, using a transperineal extended SB scheme with a median of 24 cores. In a subanalysis (data not shown) we could demonstrate that in the Heidelberg subgroup the software-assisted approach missed 4% of sPC as compared to the systematic saturation biopsy, whereas the cognitive-fusion biopsy approach at UCLH missed 9% of sPC. Therefore, the differences in prevalence are not fully explainable by different TB approaches.

We prospectively used PI-RADSv1.0, while v2.0 has recently become the favoured approach, since the time period for data accrual predominantly was before publication of v2.0. As the original RM was constructed using v1.0, the retrospective MR reading at UCLH also used v1.0. However, data are still not fully decisive as to the advantage of either over the other version. In a recent meta-analysis, a higher pooled sensitivity (0.95) for v2.0 compared to v1.0 (0.88) but a comparable pooled specificity (0.73 versus 0.75) were detected [35]. Contrary, Auer found a significantly larger discrimination for PI-RADSv1.0 (0.96) versus v2.0 (0.90) [36]. However, utilization of PI-RADSv1.0 is a common problem of recent RMs, and data on the impact of v1.0 versus v2.0 on RMs are lacking [10,15]. When retrospectively reading MR scans according to PI-RADSv2.0, we could demonstrate the discrimination performance of PI-RADSv2.0 in the UCLH cohort was higher than for PI-RADSv1.0 (AUC 0.89), but slightly lower in the Heidelberg subgroup (AUC 0.75). In addition, the RMs performance at UCLH would be improved when replacing PI-RADSv1.0 by v2.0 (AUC 0.89). Results for ROC curve analyses and Decision curve analyses are given in S2 Fig. However, we did not develop a
completely novel RM, as the purpose of our study was to validate an existing one. Additionally, when all available risk models combining clinical and MR parameters are analysed, the predictive performance of standardized MR reading is comparable when using PI-RADSv1.0 in the studies of Alberts et al., van Leeuwen et al. and the original RM, or PI-RADSv2.0 in the study of Mehralivand et al. [10,11,15,37]. All risk models enhance the discrimination compared to MRI scoring and clinical parameters alone. Further investigations are needed to investigate the performance of a novel RM including PI-RADSv2.0.

In addition, costs and capacity of MRI as an upfront test have to be considered. However, the cost-effectiveness of using upfront mpMRI has been demonstrated recently [38].

The sample size of this study population is limited, in particular in the UCLH cohort. This might also affect the applicability of both, the RM and the study’s results. However, by analysing subcohorts of consecutive men in both centers, potential bias by patient selection should be decreased.

Lastly, our sPC definition of GS $\geq 3+4$ is debatable. However, to compare our results with ERSPC-RC3, GS $\geq 3+4$ was appropriate. We acknowledge that the comparison to ERSPC-RCs is not perfect, since our sPC definition did not include clinical T-staging [21]. Additionally, tumor involved core length / cancer core length had not available. Thus we could not include it into the definition of sPC.

The conclusion of this study is that the novel RM can improve the prediction of harboring sPC. If prevalence is properly acknowledged, the RM provides benefit in the decision-making process of which patient should be biopsied over clinical risk modeling and imaging alone.

Supporting information

S1 Table. Standards of Reporting of Diagnostic Accuracy (STARD) checklist.

S2 Table. Raw data of study population.

S1 Fig. Study flowchart with inclusion criteria.

S2 Fig. ROC curve analysis (a and b) and Net decision curve analysis (c and d) for the performance of mpMRI PI-RADSv1.0 (green line), ERSPC-RC3 (pink line), ERSPC-RC3+mpMRI PI-RADSv1.0 (purple line), the risk model (orange line), mpMRI PI-RADSv2.0 (grey line), ERSPC-RC3+mpMRI PI-RADSv2.0 (brown line) and the risk model with mpMRI PI-RADSv2.0 (yellow line) for Heidelberg validation cohort and UCLH validation cohort. On Net decision curve analysis, the black line is the net benefit of providing all patients with MRI/TRUS-fusion biopsy and the horizontal green line is the net benefit of providing no patients with biopsy. The net benefit provided by each prediction tool is given.

Author Contributions

Conceptualization: Jan Philipp Radtke, Caroline M. Moore.

Data curation: Jan Philipp Radtke, Francesco Giganti, Magdalena Görtz, Albrecht Stenzinger, Alex Freeman, Shonit Punwani, David Bonekamp.

Formal analysis: Jan Philipp Radtke, Francesco Giganti, Manuel Wiesenfarth, Armando Stabile, Clement Orczyk, Svenja Dieffenbacher, Magdalena Görtz, Heinz-Peter Schlemmer.
Investigation: Jan Philipp Radtke, Francesco Giganti, Jose Marenco, Clement Orczyk, Joanne Nyaboe Nyarangi-Dix, Viktoria Schütz, Svenja Diefenbacher, Albrecht Stenzinger, Wilfried Roth, Alex Freeman, Shonit Punwani, David Bonekamp.

Methodology: Jan Philipp Radtke, Manuel Wiesenfarth, Mark Emberton, Caroline M. Moore.

Project administration: Armando Stabile, Caroline M. Moore.

Resources: Wilfried Roth, Shonit Punwani.

Software: Manuel Wiesenfarth.

Supervision: Jan Philipp Radtke, Manuel Wiesenfarth, David Bonekamp, Markus Hohenfellner, Mark Emberton, Caroline M. Moore.

Validation: Jan Philipp Radtke.

Visualization: Jan Philipp Radtke.

Writing – original draft: Jan Philipp Radtke, Francesco Giganti, Armando Stabile, Veeru Kasivisvanathan, David Bonekamp, Heinz-Peter Schlemmer, Mark Emberton, Caroline M. Moore.

Writing – review & editing: Manuel Wiesenfarth.

References

1. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384: 2027–35. https://doi.org/10.1016/S0140-6736(14)60525-0 PMID: 25108889

2. Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015; 1–9. https://doi.org/10.1016/j.eururo.2015.01.013 PMID: 25656809

3. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018; NEJMoa1801993. https://doi.org/10.1056/NEJMoa1801993 PMID: 29552975

4. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license; 2017; 6736: 32401–1. https://doi.org/10.1016/S0140-6736(16)32401-1

5. van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multimodality Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Mu. Eur Urol. 2018; https://doi.org/10.1016/j.eururo.2018.11.023 PMID: 30477981

6. Drost FJ, Osses DF, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate MRI, with or without targeted biopsy and standard biopsy for detecting prostate cancer: A Cochrane systematic review and meta-analysis. Cochrane Database Syst Rev. 2019; No.: CD012663. https://doi.org/10.1016/s1569-9056(19)30534-2

7. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MGM. Magnetic Resonance Imaging–targeted Biopsy May Enhance the Diagnostic Accuracy of Significant Prostate Cancer Detection Compared to Standard Transrectal Ultrasound-guided Biopsy: A Systematic Review and Meta-analysis. Eur Urol. European Association of Urology; 2014; 1–13. https://doi.org/10.1016/j.eururo.2014.11.037 PMID: 25480312

8. Valerio M, Donaldson I, Emberton M, Ehdai B, Hadashchik BA, Marks LS, et al. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: A systematic review. Eur Urol. European Association of Urology; 2015; 68: 8–19. https://doi.org/10.1016/j.eururo.2014.10.026 PMID: 25454618
9. Moore CM, Robertson NL, Arsaniou N, Middleton T, Villers A, Klotz L, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013; 63: 125–40. https://doi.org/10.1016/j.eururo.2012.06.004 PMID: 22743165

10. Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer—Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. 2017; 72. https://doi.org/10.1016/j.eururo.2017.03.039 PMID: 28400169

11. Mehralivand S, Shih JH, Rais–Bahrami S, Oto A, Bednarova S, Nix JW, et al. A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncol. 2018; 20892: 1–8. https://doi.org/10.1001/jamaoncol.2017.5667

12. Bjurlin MA, Rosenkrantz AB, Sarkar S, Lepor H, Huang WC, Huang R, et al. Prediction of Prostate Cancer Risk among Men Undergoing Combined MRI-Targeted and Systematic Biopsy Using Novel Pre-Biopsy Nomograms That Incorporate MRI Findings. Urology. Elsevier Inc.; 2017; https://doi.org/10.1016/j.urology.2017.09.035 PMID: 29155186

13. Kim EH, Weaver JK, Shetty AS, Vetter JM, Andriole GL, Strope SA. Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10%. Urology. 2017; 102: 183–189. https://doi.org/10.1016/j.urology.2016.08.074 PMID: 27919868

14. Dwivedi DK, Kumar R, Dwivedi AK, Bora GS, Thulkar S, Sharma S, et al. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naïve men with prostate-specific antigen between 4-10ng/mL. J Magn Reson Imaging, 2017; https://doi.org/10.1002/jmri.25850 PMID: 28872226

15. Alberts AR, Roobol MJ, Verbeek JFM, Schouts IG, Chiu PK, Osses DF, et al. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol. 2018; https://doi.org/10.1016/j.eururo.2018.07.031 PMID: 30082150

16. Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015; 351: h3688. https://doi.org/10.1136/bmj.h3688 PMID: 26264962

17. Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al. Multiparametric Magnetic Resonance Imaging (MRI) and MRI–Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol. European Association of Urology; 2016; 70: 846–853. https://doi.org/10.1016/j.eururo.2015.12.052 PMID: 26810346

18. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22: 746–757. https://doi.org/10.1007/s00330-011-2377-y PMID: 22322308

19. Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer. 2017; 116: 1159–1165. https://doi.org/10.1038/bjc.2017.57 PMID: 28350785

20. Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol. 2012/10/16. 2013; 189: 860–866. https://doi.org/10.1016/j.juro.2012.10.009 PMID: 23063807

21. Roobol MJ, van Vuut H a., Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators. Eur Urol. 2012; 61: 577–583. https://doi.org/10.1016/j.eururo.2011.11.012 PMID: 22104592

22. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013/03/30. 2013; 64: 544–552. https://doi.org/10.1016/j.eururo.2013.03.030 PMID: 23537686

23. Iasonos A, Schrag D, Raj G V, Panageas K. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364–1370. https://doi.org/10.1200/JCO.2007.12.9791 PMID: 18333559

24. Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika. 1979; 66: 403–411.

25. Janssen KJM, Vergouw E, Kalkman CJ, Grobbee DE, Moons KGM. A simple method to adjust clinical prediction models to local circumstances. Can J Anesth. 2009; 56: 194–201. https://doi.org/10.1007/s12630-009-9041-x PMID: 19247740

26. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008; 8: 53. https://doi.org/10.1186/1472-6947-8-53 PMID: 19036144
27. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology. 2003; 226:24–8. https://doi.org/10.1148/radiol.2261021292 PMID: 12511664

28. Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary Europe. BJU Int. 2015; 117: 401–8. https://doi.org/10.1111/bju.13314 PMID: 26332503

29. Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. European Association of Urology; 2019; 75: 582–590. https://doi.org/10.1016/j.eururo.2018.11.040 PMID: 30522912

30. Wegelin O, van Melick HHE, Hooff L, Bosch JLHR, Reitsma HB, Barentsz JO, et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? Eur Urol. European Association of Urology; 2017; 71: 517–531. https://doi.org/10.1016/j.eururo.2016.07.041 PMID: 27568655

31. Yaxley AJ, Yaxley JW, Thangasamy IA, Ballard E, Pokorny MR. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3–5 MRI lesions. BJU Int. 2017; 43–50. https://doi.org/10.1111/bju.13971 PMID: 28749035

32. Hamid S, Donaldson IA, Hu Y, Rodell R, Villarini B, Bonmati E, et al. The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. Eur Urol. 2019; https://doi.org/10.1016/j.eururo.2018.08.007 PMID: 30527787

33. Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng F-M, et al. A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging-Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial. Eur Urol. European Association of Urology; 2013; 66: 343–351. https://doi.org/10.1016/j.eururo.2013.10.048

34. Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy—prospective multicenter study. Radiology. 2013/04/13. 2013; 268: 461–469. https://doi.org/10.1148/radiol.13121501 PMID: 23579051

35. Woo S, Hyun C, Youn S, Yeon J, Hyup S, Novara G. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol. European Association of Urology; 2017; https://doi.org/10.1016/j.euro.2017.01.042 PMID: 28196723

36. Auer T, Edlinger M, Bektic J, Nagele U, Herrmann T, Schäfer G, et al. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results. World J Urol. 2016; doi:10.100

37. van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017; n/a-n/a. https://doi.org/10.1111/bju.13814 PMID: 28207961

38. Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. European Association of Urology; 2017;10.1016/j.euro.2017.08.018 PMID: 28935163